多柔比星脂质体在Ⅱ、Ⅲ期乳腺癌新辅助化疗中的临床疗效

doi:10.3969/j.issn.1671-7171.2022.04.019

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1308 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical effect of doxorubicin liposomes in neoadjuvant chemotherapy for stage Ⅱ and Ⅲ breast cancer. 【Methods】Eighty two patients with stage Ⅱ-Ⅲ breast cancer who were admitted to our hospital were recruited in the study. Patients were divided into the observation group and the control group by random method, with 41 cases in each group. The control group received doxorubicin 40 mg/m² combined with cyclophosphamide 600 mg/m², sequentially followed by docetaxel 85 mg/m² neoadjuvant chemotherapy, while the observation group received doxorubicin liposome 40 mg/m² combined with cyclophosphamide 600 mg/m² followed by docetaxel 85 mg/m² chemotherapy for 8 cycles of treatment. The clinical efficacy, surgical treatment and postoperative pathology of the two groups were compared between the two groups. and the incidence of adverse reactions during neoadjuvant chemotherapy were counted. Follow up the survival of the two groups were followed up and performed Kaplan-Meier survival analysis. 【Results】There were no statistically significant differences between the two groups in treatment efficiency, clinical control rate, disease control rate, pathological complete remission rate, and axillary lymph node conversion rate (P>0.05). During the neoadjuvant chemotherapy between the two groups, the incidence of grade Ⅰ~Ⅱ myocardial damage and grade Ⅰ~Ⅱ hand-foot syndrome in the observation group was lower than those in the control group, and the differences were statistically significant (P<0.05). There was no significant difference in the incidence of other side effects between the two groups (P>0.05). Kaplan-Meier survival analysis showed that the 3-year progression-free survival curve of the observation group was better than that of the control group (P<0.05), however, there was no statistically significant difference in the overall survival curve between the two groups (P>0.05). 【Conclusion】The short-term effect of doxorubicin liposome combined with cyclophosphamide sequentially followed by docetaxel neoadjuvant chemotherapy for patients with stage Ⅱ and Ⅲ breast cancer is definitely effective, which can reduce the incidence of myocardial damage and hand-foot syndrome, and prolong progression-free survival, but has no significant effect on overall survival.

Key words： Breast Neoplasms/DT Doxorubicin/TU Antineoplastic Combined Chemotherapy Protocols Treatment Outcome

Received: 28 September 2021

PACS:

R737.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Qian-qian
	HONG Yue-yan
	WU Xuan

Cite this article:

HAN Qian-qian,HONG Yue-yan,WU Xuan. Clinical Effect of Doxorubicin Liposomes in Neoadjuvant Chemotherapy for Stage Ⅱ and Ⅲ Breast Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(4): 546-549.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.04.019 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I4/546

[1] COUGHLIN S S. Epidemiology of breast cancer in women[J].Adv Exp Med Biol,2019,1152:9-29.
[2] 呼改凤,付海霞,马继芳,等. 蒽环类药物对早期乳腺癌术后患者心脏毒性影响的临床研究[J].中华心血管病杂志,2018,46(12):987-992.
[3] CHENG Y,ZOU T,DAI M,et al. Doxorubicin loaded tumor-triggered targeting ammonium bicarbonate liposomes for tumor-specific drug delivery [J].Colloids Surf B Biointerfaces,2019,178:263-268.
[4] 张改琴,任毅,厉锋,等. 多柔比星脂质体与表柔比星在乳腺癌化疗中的疗效对比[J].现代仪器与医疗,2017,23(6):28-29.
[5] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J].中国癌症杂志,2017,27(9):695-759.
[6] EISENHAUER E A,THERASSE P,BOGAERTS J,et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[7] 王晓稼. 乳腺癌新辅助化疗的共识与争议[J].中国肿瘤,2007,16(10):788-792.
[8] BOYD M R,PAULL K D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen[J].Drug Dev Res,2010,34(2):91-109.
[9] MITTENDORF EA,ZHANG H,BARRIOS CH,et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031):a randomised,double-blind,phase 3 trial[J].Lancet,2020,396(10257):1090-1100.
[10] 刘晓丽,张文华,宋昕殊,等. 应用三维斑点追踪技术评价蒽环类药物对乳腺癌化疗患者心肌损害及转归[J].中国超声医学杂志,2019,35(8):696-699.
[11] JERUSALEM G,LANCELLOTTI P,KIM S B. HER2+ breast cancer treatment and cardiotoxicity:monitoring and management[J].Breast Cancer Res Treat,2019,177(2):237-250.
[12] CAPARICA R,BRUZZONE M,POGGIO F,et al. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients:a systematic review and meta-analysis of randomized controlled trials [J].Breast Cancer Res Treat,2019,174(1):27-37.
[13] EL-AGAMA S E,ABDEL-AZIZ A K,ESMAT A,et al. Chemotherapy and cognition:comprehensive review on doxorubicin-induced chemobrain [J].Cancer Chemother Pharmacol,2019,84(1):1-14.